Immune Response to Expand HIV Trial
Posted on: Monday, 19 June 2006, 15:00 CDT
The Immune Response Corp. said Monday it has received the go-ahead to expand its phase 2 trial of a new HIV treatment.
The company said it has completed the first stage of enrollment of drug-naive HIV patients in the phase 2 study of IR103, set in Italy.
The trial -- including 31 patients from a previous trial of IRC's immunotherapy Remune, and 54 new patients -- will test IR103 as a first-line therapy for drug-naive HIV patients who are not yet recommended for antiretroviral therapy under current medical guidelines.
The study will ultimately enroll more than 200 drug-naive patients in two parallel studies in Italy, France, Canada and the U.K., IRC said, and will assess the safety and effectiveness of IR103 in inducing HIV-specific immunity.
Source: United Press International
Related Articles
- Ending of HIV Vaccine Trial Jolts Industry
- ZIOPHARM Treats Patients in U.S. Phase I Trials of Oral Darinaparsin and Indibulin
- Seventy-Eight Percent of Newly Diagnosed Dyslipidemia Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
- Fresh Hope for Patients With Kidneycancer As New Drug Gains a Licence
- New HIV Vaccine Trials to Begin in Uganda
- Thomas Land Publishers Names Leading Scientist Editor-in-Chief of HIV Clinical Trials
- Portugal Has 10 Percent HIV Infection Rate Among Drug Users: EU Agency
- Cellegy Announces Update to Savvy Phase 3 HIV Prevention Trials
- Ulster Breast Cancer Patient in Battle for Wonder Drug
- Cellegy Announces 50% Enrollment in Phase 3 HIV Prevention Trial in Ghana
User Comments (0)
RSS Feeds